Edgewise Therapeutics, Inc. (EWTX) Stock: Price, Forecast & Analyst Target
Edgewise Therapeutics, Inc. (EWTX) — MoonshotScore 84/100 (Exceptional band), calculated Nov 18, 2026. Price $41.17 (-0.48%), as of the Nov 19, 2026 trading session; market cap $4.51B.
Educational signal · not a buy or sell recommendation · How to read this
Edgewise Therapeutics, Inc. · EWTX · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Edgewise is developing small-molecule treatments for rare muscle diseases, with its lead program addressing the genetic causes of Duchenne and Becker muscular dystrophy. The company has cleared its initial clinical phase and now faces the fundamental question that defines pre-commercial biotech: whether the science that works in the lab translates to patient outcomes in later trials. Cash reserves are substantial, but the company has never generated revenue from its therapeutic candidates.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Edgewise Therapeutics (EWTX)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a fortress balance sheet, but weak growth; the market is already moving on it. Business Quality: Solid; Financial Safety: Fortress; Valuation: Fair; Growth Durability: Fading; Momentum: Surging.
- EPS beat 5 of the last 8 reports
- Altman Z 22.08 · Piotroski F 3
- ROE 130.4% · ROA 56.7% · current ratio 12.30 · earnings yield 20.8% · free-cash-flow yield -4.2%
Holding back: soft growth
Helping: business quality, balance-sheet strength, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 85 | Exceptional | |
| 85 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $41.17 | |
| Change on the day | -0.48% | |
| 52-week range | $19.76–$48.78 | |
| Market capitalisation | $4.51B | — |
| Price / earnings (trailing) | 4.54 | |
| Shares traded on the day | 1.19M | |
| Beta (volatility vs the S&P 500) | 0.28 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Edgewise Therapeutics (EWTX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Edgewise Therapeutics (EWTX), and what does it report?
Short answer · as of
Edgewise operates as a precision medicine company, engineering compounds designed to modulate key muscle proteins in patients with specific genetic conditions.
Research dated 2026-09-13.
The company generates no product revenue; its financials measure only research spending, which expanded significantly as the lead candidate progressed through early-stage clinical work. The core business model assumes future licensing or commercialization opportunities, with analyst expectations building in revenue inflection points well into the next cycle.
What do the latest results show for Edgewise Therapeutics (EWTX)?
Short answer · as of
Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Research dated 2026-09-13.
The most recent quarter shows losses widening from the prior period as research and development spending accelerated. This trend follows the expected pattern for companies in clinical development: burn rate increases when a program moves deeper into testing. The latest earnings reports show management's cost structure remains disciplined relative to cash resources, with R&D intensity expanding while general and administrative expenses stayed modest in absolute terms.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
What are the financial strengths and risks for Edgewise Therapeutics (EWTX)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
The company's financial position is characterized by a large cash balance relative to current burn rate, though the cash runway depends entirely on whether development timelines extend. Balance sheet risk is low; debt is minimal and liquidity ratios reflect strong defensive positioning. The central vulnerability is clinical: if efficacy or safety questions emerge in later trials, the valuation multiple would face significant pressure regardless of cash sufficiency. Institutional ownership has grown, suggesting confidence among sophisticated investors in the underlying science.
What should you watch next at Edgewise Therapeutics (EWTX)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $2.27M · EPS 8.98 · 8 analysts.
Research dated 2026-09-13.
Readers should track clinical milestones closely, particularly data readouts that would confirm efficacy in the target indication. Analyst estimates currently assume the company will reach revenue-generating status, and interim trial results will either validate or challenge those projections. Management has signaled timelines for upcoming data presentations; watch whether results match the expectations embedded in analyst price targets. Cash runway at current burn rates provides cushion, but extended development timelines would require capital raises that could dilute shareholders.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for EWTX.
Checked against the records this page reads, on the dates shown above.
How does Edgewise Therapeutics compare with its peers?
Short answer
Edgewise Therapeutics's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with other pre-commercial biotechs developing treatments for rare genetic muscle diseases, Edgewise's differentiation rests on its mechanism—modulation of muscle proteins rather than gene therapy—and the specificity of its patient population. Other companies in the space pursue different molecular targets or broader disease indications; this company's narrower focus trades off market size for reduced development complexity. Analyst ratings are more favorable than the sector median, reflecting confidence in the approach, though that confidence remains conditional on clinical proof.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $13.56 Nov 18, 2026 | $3.01B | 97 5-pillar Nov 18, 2026 | |
| $58.26 Nov 19, 2026 | $2.97B | 95 5-pillar Nov 18, 2026 | |
| $27.61 Nov 18, 2026 | $3.49B | 89 5-pillar Nov 18, 2026 | |
| Edgewise Therapeutics (EWTX) — this page | $41.17 | $4.51B | 84 |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $46.41 Nov 19, 2026 | $3.42B | 72 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $17.83 Nov 18, 2026 | $3.08B | 68 5-pillar Nov 18, 2026 | |
| $14.22 Nov 19, 2026 | $4.99B | 67 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $124.39 Nov 19, 2026 | $5.25B | 66 5-pillar Nov 18, 2026 | |
| $26.20 Nov 19, 2026 | $3.37B | 66 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $36.00 – $85.00
- Consensus target
- $55.33
- Median target
- $52.00
- Revenue estimate
- $2.27M
- EPS estimate
- $8.98
Consensus record · Captured .
Measured against a quoted price of $41.17 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 75
- Identified insiders
- 13
- Purchases
- 0
- Sales
- 22
- Other transactions
- 53
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held EWTX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported EWTX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Edgewise Therapeutics (EWTX)?
Common Questions About EWTX (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is the lead oral dystrophinopathy treatment?
The lead program is an orally administered compound engineered to address the genetic causes of dystrophinopathies, a family of muscle-wasting disorders. The drug's design targets a specific molecular pathway rather than attempting whole-gene replacement, which may offer practical advantages in patient administration and manufacturing scalability.
Does the company have enough cash to reach clinical milestones?
Cash reserves cover current burn rates across multiple years, providing sufficient runway for the planned clinical program progression. The company's burn trajectory has remained relatively controlled, with spending increases tied to trial expansion rather than cost inflation. Whether this proves adequate depends on whether development timelines extend beyond current expectations.
Why do analysts expect revenue to start so far in the future?
Analyst projections assume the company must complete later-stage clinical trials, obtain regulatory approval, and establish commercial infrastructure before generating meaningful product sales. For rare-disease biotechs, this sequence typically spans multiple years of development. Analyst estimates reflect the typical clinical-stage risk curve rather than confidence in a near-term inflection point.
Are company insiders buying or selling the stock?
Recent insider activity shows share dispositions that appear consistent with equity compensation vesting rather than opportunistic purchases. No recent buy signals from management were reported; insider transactions are concentrated in awards and exemptions typical of pre-commercial biotech organizations where equity serves as the primary compensation lever.
What is the EWTX stock price today?
The last price recorded for Edgewise Therapeutics, Inc. (EWTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the EWTX price target?
The analyst consensus price target for Edgewise Therapeutics, Inc. (EWTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 17 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com